Micafungin for the treatment of neonatal invasive candidiasis;Utilidad clínica de la micafungina en el tratamiento de las candidiasis invasoras en el neonato

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 56-61

  Infante López, María Elena ^a   Rojo Conejo, Pablo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Antifungals; Candidemia; Candidiasis; Efficacy; Micafungin; Neonates; Pharmacokinetics; Preterm babies; Safety

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DIARRHEA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; EMBASE; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INVASIVE CANDIDIASIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MEDICAL RESEARCH; MEDLINE; NAUSEA AND VOMITING; NEWBORN; NEWBORN CARE; NEWBORN INTENSIVE CARE; NEWBORN MORBIDITY; NEWBORN MORTALITY; PREVALENCE; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGE FACTORS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; FEMALE; FUNGEMIA; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LIPOPEPTIDES; MALE; META-ANALYSIS AS TOPIC; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

CANDIDA; CANDIDA ALBICANS;

EID: 67650732637     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70009-9     Document Type: Review

References (40)

1. Almirante B., and Rodríguez D. Antifungal agents in neonates: issues and recommendations. Paediatr Drugs 9 (2007) 311-321
2. Arrieta A. Micafungina in pediatric patients: assessment of safety in clinical trials. 47th Interscience Conference on Antimicrobial Agents and Chemoterapy. Chicago (2007) Poster M.1162
3. Ashouri N., Singh J., and Arrieta A. Micafungin in pediatrics: when one size does not fit all. Expert Opin Drug Metab Toxicol 4 (2008) 463-469
4. Baley J.E., Kliegman R.M., and Fanaroff A.A. Disseminated fungal infections in very lowbirth-weight infants: therapeutictoxicity. Pediatrics 73 (1984) 153-157
5. Benjamin Jr. D.K., Poole C., Steinbach W.J., Rowen J.L., and Walsh T.J. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 112 (2003) 634-640
6. Benjamin Jr. D.K., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh W., Higgins R.D., Duara S., Poole K., Laptook A., and Goldberg R. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 117 (2006) 84-92
7. Cagnoni P.J. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 49 (2002) S81-S86
8. Chapman R.L., and Faix R.G. Invasive neonatal candidiasis: an overview. Semin Perinatol 27 (2003) 352-356
9. Clerihew L., Lamagni T.L., Brocklehurst P., and McGuire W. Invasive fungal infection in very low birthweight infants: national prospective surveillance study. Arch Dis Child Fetal Neonatal Ed 91 (2006) 188-192
10. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
11. Frattarelli D.A., Reed M.D., Giacoia G.P., and Aranda J.V. Antifungals in systemic neonatal candidiasis. Drugs 64 (2004) 949-968
12. Gafter-Gvili A., Vidal L., Goldberg E., Leibovici L., and Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 83 (2008) 1011-1021
13. Heresi G.P., Gerstmann D.R., Reed M.D., Van den Anker J.N., Blumer J.L., Kovanda L., Keirns J.J., Buell D.N., and Kearns G.L. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 25 (2006) 1110-1115
14. Hope W.W., Mickiene D., Petraitis V., Petraitiene R., Kelaher A.M., Hughes J.E., Cotton M.P., Bacher J., Keirns J.J., Buell D., Heresi G., Benjamin Jr. D.K., Groll A.H., Drusano G.L., and Walsh T.J. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 197 (2008) 163-171
15. Hope W.W., Seibel N.L., Schwartz C.L., Arrieta A., Flynn P., Shad A., Albano E., Keirns J.J., Buell D.N., Gumbo T., Drusano G.L., and Walsh T.J. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51 (2007) 3714-3719
16. Mycamine. Micafungina (sal sódica para perfusión). Ficha técnica. Astellas Pharma Europe.
17. Kossoff E.H., Buescher E.S., and Karlowicz M.G. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 17 (1998) 504-508
18. Kullberg B.J., Sobel J.D., Ruhnke M., Pappas P.G., Viscoli C., Rex J.H., Cleary J.D., Rubinstein E., Church L.W., Brown J.M., Schlamm H.T., Oborska I.T., Hilton F., and Hodges M.R. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
19. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H., and Cornely O.A. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
20. Levy I., Rubin L.G., Vasishtha S., Tucci V., and Sood S.K. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26 (1998) 1086-1088
21. López Sastre J.B., Coto Cotallo G.D., and Fernández Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 20 (2003) 153-163
22. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., Lupinacci R., Sable C., Kartsonis N., Perfect J., and Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
23. Nakamura T., and Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 12 (2006) 132-138
24. Odio C.M., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., Sàenz A., Herrera M.L., and Walsh T.J. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 23 (2004) 1093-1097
25. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., Lipton J., Jacobs P., Van Rensburg J.H., Rex J.H., Lau W., Facklam D., and Buell D.N. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661
26. Pachón J., Cisneros J.M., Collado-Romacho A.R., Lomas-Cabezas J.M., Lozano de León-Naranjo F., Parra-Ruiz J., and Rivero-Román A. Sociedad Andaluza de Enfermedades Infecciosas. Treatment of invasive fungal infections 2005. Andalusian Infectious Disease Society. Enferm Infecc Microbiol Clin 24 (2006) 254-263
27. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., and Edwards J.E. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
28. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., Vazquez J.A., Dupont B.F., Horn D.L., Ostrosky-Zeichner L., Reboli A.C., Suh B., Digumarti R., Wu C., Kovanda L.L., Arnold L.J., and Buell D.N. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
29. Pettengell K., Mynhardt J., Kluyts T., Lau W., Facklam D., and Buell D. Successful treatment of oesophageal candidiasis by micafungin FK463: a novel systemic antifungal agent.Alimen?. Pharmacol Ther 20 (2004) 475-481
30. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
31. Prasad P.A., Coffin S.E., Leckerman K.H., Walsh T.J., and Zaoutis T.E. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 27 (2008) 1083-1088
32. Queiroz-Telles F., Berezin E., Leverger G., Freire A., Van der Vyver A., Chotpitayasunondh T., Konja J., Diekmann-Berndt H., Koblinger S., Groll A.H., and Arrieta A. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27 (2008) 820-826
33. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., Betts R., Wible M., Goldstein B.P., Schranz J., Krause D.S., and Walsh T.J. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
34. Rodriguez D., Almirante B., Park B.J., Cuenca-Estrella M., Planes A.M., Sanchez F., Gene A., Xercavins M., Fontanals D., Rodriguez-Tudela J.L., Warnock D.W., and Pahissa A. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 25 (2006) 224-229
35. Saiman L., Ludington E., Pfaller M., Rangel-Frausto S., Wiblin R.T., Dawson J., Blumberg H.M., Patterson J.E., Rinaldi M., Edwards J.E., Wenzel R.P., and Jarvis W. Risk factors for candidemia in Neonatal Intensive Care Unit patients. Pediatr Infect Dis J 19 (2000) 319-324
36. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., Keirns J., Lau W.M., Facklam D.P., Buell D.N., and Walsh T.J. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49 (2005) 3317-3324
37. Smith P.B., Walsh T.J., and Hope W. Pharmacokinetics of an elevated dose of micafungin in premature neonates. 47th Interscience Conference on Antimicrobial Agents and Chemoterapy. Chicago (2007) Abstract A-776a
38. Steinbach W.J., and Benjamin D.K. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 18 (2005) 484-489
39. Stoll B.J., Hansen N., Fanaroff A.A., Wright L.L., Carlo W.A., Ehrenkranz R.A., Lemons J.A., Donovan E.F., Stark A.R., Tyson J.E., Oh W., Bauer C.R., Korones S.B., Shankaran S., Laptook A.R., Stevenson D.K., Papile L.A., and Poole W.K. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110 (2002) 285-291
40. Van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., and Walsh T.J. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416